首页> 美国卫生研究院文献>Oncotarget >Long non-coding RNA LINC01133 represses KLF2 P21 and E-cadherin transcription through binding with EZH2 LSD1 in non small cell lung cancer
【2h】

Long non-coding RNA LINC01133 represses KLF2 P21 and E-cadherin transcription through binding with EZH2 LSD1 in non small cell lung cancer

机译:长非编码RNA LINC01133通过与非小细胞肺癌中的EZH2LSD1结合来抑制KLF2P21和E-钙粘蛋白的转录

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Long non-coding RNAs are emerging as crucial regulators and prognostic markers in multiple cancers including non small cell lung cancer (NSCLC). In this study, we screened LINCO1133 as a new candidate lncRNA which promotes NSCLC development and progression, in two independent datasets ( and ) from the Gene Expression Omnibus (GEO). LINC01133 is previously found to be over-expressed in lung squamous cell cancer (LSCC) and knockdown its expression inhibits LSCC cells invasion. However, its' molecular mechanism and downstream targets involving in regulation of cancer cells phenotype is not known. Here, we found that LINC01133 expression is up-regulated in NSCLC tissues, and its' over-expression is associated with patients poor prognosis and short survival time. LINC01133 knockdown decreased NSCLC cells proliferation, migration, invasion and induced cell cycle G1/S phase arrest and cell apoptosis. Mechanistic investigations showed that LINC01133 could interact with EZH2, LSD1 and recruit them to KLF2, P21 or E-cadherin promoter regions to repress their transcription. Furthermore, rescue experiments demonstrated that LINC01133 oncogenic function is partly through regulating KLF2. Lastly, we found that there was negative correlation between LINC01133 and KLF2, P21 or E-cadherin in NSCLC. Overall, our findings illuminate how LINC01133 over-expression confers an oncogenic function in NSCLC that may offer a novel therapy target in this disease.
机译:长的非编码RNA在包括非小细胞肺癌(NSCLC)在内的多种癌症中正成为重要的调节剂和预后标志物。在这项研究中,我们从基因表达综合(GEO)的两个独立数据集中(和),将LINCO1133筛选为可促进NSCLC发育和进展的新候选lncRNA。先前发现LINC01133在肺鳞状细胞癌(LSCC)中过表达,而敲低其表达可抑制LSCC细胞的侵袭。然而,尚不清楚其调控癌细胞表型的分子机制和下游靶标。在这里,我们发现LINC01133在NSCLC组织中表达上调,其过表达与患者预后差和生存时间短有关。 LINC01133抑制可降低NSCLC细胞的增殖,迁移,侵袭并诱导细胞周期G1 / S期阻滞和细胞凋亡。机理研究表明,LINC01133可以与EZH2,LSD1相互作用并将它们募集到KLF2,P21或E-钙粘蛋白启动子区域,以抑制其转录。此外,救援实验表明,LINC01133致癌功能部分是通过调节KLF2来实现的。最后,我们发现LINC01133与NSCLC中的KLF2,P21或E-钙粘蛋白呈负相关。总体而言,我们的发现阐明了LINC01133过表达如何赋予NSCLC致癌功能,该功能可能为该疾病提供新的治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号